Literature DB >> 2615722

Effect of 1,25-dihydroxyvitamin D3 in vivo on circulating T lymphocytes.

J M Bargman1, E D Silverman, M H Klein.   

Abstract

Previous in vitro and animal studies have suggested that 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] has important immunoregulatory properties. In this study, immune parameters were monitored in 16 patients the day before and 14 days after starting therapy with this hormone. Despite the absence of changes in the total white cell count, lymphocyte count and T lymphocyte count, CD4/CD8 ('helper/suppressor') ratio of T lymphocytes increased by 57% from the normal into the elevated range. Furthermore, a downward trend was seen in the percentage of stimulated lymphocytes expressing the interleukin-2 receptor. We conclude that in vivo administration of 1,25(OH)2D3 may have immunoregulatory effects in man. Whether these changes are the result of changes in intracellular or extracellular calcium concentration, parathyroid hormone concentration, or the concentration of 1,25(OH)2D3 itself remains to be answered.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2615722

Source DB:  PubMed          Journal:  Miner Electrolyte Metab        ISSN: 0378-0392


  3 in total

1.  Randomised controlled trial of vitamin D supplementation on bone density and biochemical indices in preterm infants.

Authors:  M C Backström; R Mäki; A L Kuusela; H Sievänen; A M Koivisto; R S Ikonen; T Kouri; M Mäki
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-05       Impact factor: 5.747

2.  CD8(+) T cells are not necessary for 1 alpha,25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice.

Authors:  Terrence F Meehan; Hector F DeLuca
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-02       Impact factor: 11.205

3.  Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate.

Authors:  Fabian Sierra Morales; Igor J Koralnik; Shiva Gautam; Soleil Samaan; Jacob A Sloane
Journal:  J Neurol       Date:  2019-10-03       Impact factor: 4.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.